株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

卵巣癌:パイプライン製品の分析

Ovarian Cancer - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 229719
出版日 ページ情報 英文 2232 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.48円で換算しております。
Back to Top
卵巣癌:パイプライン製品の分析 Ovarian Cancer - Pipeline Review, H2 2017
出版日: 2017年12月29日 ページ情報: 英文 2232 Pages
概要

卵巣癌の大多数は、卵巣の上皮(外膜)に発生します。卵巣癌の兆候や症状には、骨盤の不快感や痛み、消化不良、悪心、便秘といった排便サイクルの変化、食欲不振、腰痛などがあります。この疾患の素因には、加齢と家系が大きくかかわっています。

当レポートでは、卵巣癌治療薬におけるパイプライン製品の概要や治験の段階別の製品概要、主要企業のプロファイル、薬剤のプロファイル、パイプライン製品の最新動向などを提供しています。

イントロダクション

卵巣癌の概要

治療薬の開発

卵巣癌:企業で開発中の治療薬

卵巣癌:大学/機関で研究中の治療薬

卵巣癌:パイプライン製品の概況

卵巣癌:企業で開発中の製品

卵巣癌:大学/機関で研究中の製品

卵巣癌の治療薬開発に従事している企業

卵巣癌:治療薬の評価

薬剤プロファイル

卵巣癌:休止中のプロジェクト

卵巣癌:開発が中止された製品

卵巣癌:製品開発のマイルストーン

付録

目次
Product Code: GMDHC10022IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer - Pipeline Review, H2 2017, provides an overview of the Ovarian Cancer (Oncology) pipeline landscape.

Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ovarian Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 2, 14, 141, 144, 7, 221, 26 and 10 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 10, 12, 45 and 8 molecules, respectively.

Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ovarian Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ovarian Cancer (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ovarian Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Ovarian Cancer - Overview
  • Ovarian Cancer - Therapeutics Development
  • Ovarian Cancer - Therapeutics Assessment
  • Ovarian Cancer - Companies Involved in Therapeutics Development
  • Ovarian Cancer - Drug Profiles
  • Ovarian Cancer - Dormant Projects
  • Ovarian Cancer - Discontinued Products
  • Ovarian Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Ovarian Cancer, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Ovarian Cancer - Pipeline by 3-V Biosciences Inc, H2 2017
  • Ovarian Cancer - Pipeline by 4SC AG, H2 2017
  • Ovarian Cancer - Pipeline by AB Science SA, H2 2017
  • Ovarian Cancer - Pipeline by AbbVie Inc, H2 2017
  • Ovarian Cancer - Pipeline by AbGenomics International Inc, H2 2017
  • Ovarian Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2017
  • Ovarian Cancer - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H2 2017
  • Ovarian Cancer - Pipeline by Advanced Cancer Therapeutics LLC, H2 2017
  • Ovarian Cancer - Pipeline by Advantagene Inc, H2 2017
  • Ovarian Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017
  • Ovarian Cancer - Pipeline by Aeterna Zentaris Inc, H2 2017
  • Ovarian Cancer - Pipeline by Alethia Biotherapeutics Inc, H2 2017
  • Ovarian Cancer - Pipeline by AlfaSigma SpA, H2 2017
  • Ovarian Cancer - Pipeline by Alkermes Plc, H2 2017
  • Ovarian Cancer - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H2 2017
  • Ovarian Cancer - Pipeline by Almac Discovery Ltd, H2 2017
  • Ovarian Cancer - Pipeline by Alpha Cancer Technologies Inc, H2 2017
  • Ovarian Cancer - Pipeline by Alteogen Inc, H2 2017
  • Ovarian Cancer - Pipeline by Altor BioScience Corp, H2 2017
  • Ovarian Cancer - Pipeline by Ambrx Inc, H2 2017
  • Ovarian Cancer - Pipeline by Amgen Inc, H2 2017
  • Ovarian Cancer - Pipeline by Amunix Operating Inc, H2 2017
  • Ovarian Cancer - Pipeline by Anavex Life Sciences Corp, H2 2017
  • Ovarian Cancer - Pipeline by ANP Technologies Inc, H2 2017
  • Ovarian Cancer - Pipeline by AntiCancer Inc, H2 2017
  • Ovarian Cancer - Pipeline by Antigen Express Inc, H2 2017
  • Ovarian Cancer - Pipeline by Antoxis Ltd, H2 2017
  • Ovarian Cancer - Pipeline by Aphios Corp, H2 2017
  • Ovarian Cancer - Pipeline by Aposense Ltd, H2 2017
  • Ovarian Cancer - Pipeline by Aprea AB, H2 2017
  • Ovarian Cancer - Pipeline by arGEN-X BV, H2 2017
  • Ovarian Cancer - Pipeline by ARMO Biosciences Inc, H2 2017
  • Ovarian Cancer - Pipeline by Armour Therapeutics Inc, H2 2017
  • Ovarian Cancer - Pipeline by ArQule Inc, H2 2017
  • Ovarian Cancer - Pipeline by Array BioPharma Inc, H2 2017
  • Ovarian Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2017
  • Ovarian Cancer - Pipeline by Astellas Pharma Inc, H2 2017
  • Ovarian Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2017
  • Ovarian Cancer - Pipeline by AstraZeneca Plc, H2 2017
  • Ovarian Cancer - Pipeline by Atara Biotherapeutics Inc, H2 2017
  • Ovarian Cancer - Pipeline by Athenex Inc, H2 2017
  • Ovarian Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2017
  • Ovarian Cancer - Pipeline by Avipep Pty Ltd, H2 2017
  • Ovarian Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2017
  • Ovarian Cancer - Pipeline by Bavarian Nordic A/S, H2 2017
  • Ovarian Cancer - Pipeline by Bayer AG, H2 2017
  • Ovarian Cancer - Pipeline by BeiGene Ltd, H2 2017
  • Ovarian Cancer - Pipeline by Bio-Path Holdings Inc, H2 2017
  • Ovarian Cancer - Pipeline by BioCancell Ltd, H2 2017
  • Ovarian Cancer - Pipeline by BioMoti Ltd, H2 2017
  • Ovarian Cancer - Pipeline by Bionomics Ltd, H2 2017
  • Ovarian Cancer - Pipeline by BioNTech AG, H2 2017
  • Ovarian Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H2 2017
  • Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2017
  • Ovarian Cancer - Pipeline by Boston Biomedical Inc, H2 2017
  • Ovarian Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2017
  • Ovarian Cancer - Pipeline by Caladrius Biosciences Inc, H2 2017
  • Ovarian Cancer - Pipeline by Calithera Biosciences Inc, H2 2017
  • Ovarian Cancer - Pipeline by CASI Pharmaceuticals Inc, H2 2017
  • Ovarian Cancer - Pipeline by Cavion LLC, H2 2017
  • Ovarian Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2017
  • Ovarian Cancer - Pipeline by Celgene Corp, H2 2017
  • Ovarian Cancer - Pipeline by Celldex Therapeutics Inc, H2 2017
  • Ovarian Cancer - Pipeline by Celleron Therapeutics Ltd, H2 2017
  • Ovarian Cancer - Pipeline by Cellular Biomedicine Group Inc, H2 2017

List of Figures

  • Number of Products under Development for Ovarian Cancer, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top